INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit [Accessibility Statement] Skip NavigationNEW YORK, Feb. 10, 2026 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no late ...

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Inovio securities between October 10, 2023 and December 26, 202 ...

Core Viewpoint - A class action lawsuit has been announced by Rosen Law Firm on behalf of purchasers of securities of Inovio Pharmaceuticals, Inc. for the period between October 10, 2023, and December 26, 2025, indicating potential legal challenges for the company [1]. Company Overview - Inovio Pharmaceuticals, Inc. is described as a biotechnology company focused on the discovery, development, and commercialization of DNA medicines aimed at treating and protecting individuals from diseases, including those associated with human papillomavirus (HPV) [1].

Core Viewpoint - A securities class action lawsuit has been filed against Inovio Pharmaceuticals, alleging that the company misled investors regarding the manufacturing deficiencies of its CELLECTRA device and the regulatory prospects of its INO-3107 BLA [1][2]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Eastern District of Pennsylvania on behalf of all individuals or entities who purchased Inovio securities between October 10, 2023, and December 26, 2025 [1]. - The complaint claims that Inovio failed to disclose significant issues, including deficiencies in manufacturing for the CELLECTRA device and the unlikelihood of submitting the INO-3107 BLA to the FDA by the second half of 2024 [2]. Group 2: Allegations Against Inovio - Allegations include that Inovio lacked sufficient information to justify the eligibility of the INO-3107 BLA for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [2]. - The public statements made by Inovio were claimed to be materially false and misleading throughout the relevant period [2]. Group 3: Investor Information - Investors who acquired shares of Inovio are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on April 7, 2026 [3].

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus ("HPV†). Robbins LLP is Investigating Allegations t ...

ATLANTA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding Inovio’s business, operations, and prospects, including allegations that: (i) manufacturing for Inovio’s CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 Biologi ...

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Inovio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Dece ...

Core Viewpoint - Inovio Pharmaceuticals is under investigation for potential violations of federal securities laws following the FDA's rejection of its accelerated approval request for INO-3107, leading to a significant drop in its stock price. Group 1: FDA Announcement - The FDA accepted Inovio's Biologics License Application (BLA) for INO-3107 for recurrent respiratory papillomatosis on a standard review timeline [2] - The FDA indicated that Inovio did not provide sufficient information to qualify for accelerated approval [2] - Inovio plans to request a meeting with the FDA to discuss pursuing accelerated approval despite the current standard review timeline [2] Group 2: Stock Market Reaction - Following the FDA announcement, Inovio's stock price fell over 24% on the same day [3] Group 3: Legal Investigation - Levi & Korsinsky has commenced an investigation into Inovio Pharmaceuticals regarding potential violations of federal securities laws [1] - The firm has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Inovio Pharmaceuticals and its officers/directors, following a significant stock price drop after FDA news regarding its drug application [1][3][4]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Inovio Pharmaceuticals, urging them to contact the firm regarding potential claims [1]. - The investigation focuses on whether Inovio and its executives have engaged in securities fraud or other unlawful practices [1]. Group 2: FDA Announcement and Stock Impact - On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107 but indicated that the company did not provide sufficient information for accelerated approval [3]. - Inovio announced it would not pursue approval under the standard review timeline and plans to meet with the FDA to discuss options for accelerated approval [3]. - Following this announcement, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Inovio Pharmaceuticals and its officers/directors, following a significant stock price drop after FDA news regarding its drug application [1][4]. Group 1: FDA Announcement and Stock Impact - On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107, a treatment for recurrent respiratory papillomatosis, but did not find sufficient information for accelerated approval [3]. - Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share on the same day [4]. Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Inovio regarding claims of potential securities fraud and is encouraging them to contact the firm for further information [1].